BIO-key International (BKYI) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
9 Oct, 2026Company overview and business model
Enterprise IAM provider offering PortalGuard and hosted PortalGuard IDaaS, with 17 authentication factors and biometric identity tools for workforce, customer and civil ID use cases.
SaaS subscriptions generate annual recurring revenue through noncancelable contracts averaging ~1 year; fees depend mainly on products used and enrolled users, with direct and channel sales.
Biometric platform supports enrollment, de-duplication and authentication at scale; one bank uses fingerprint biometrics for over 21.7 million customers in branches daily.
Swivel Secure was acquired in 2022 and now operates as BIO-key EMEA, with offices in Madrid and Lisbon and a direct sales force.
Use of proceeds and capital allocation
Resale proceeds go entirely to Armistice Capital Master Fund Ltd.; none go to the issuer. Cash exercise of all warrants could yield $5,020,872.08 gross for working capital and general corporate purposes.
Warrant exercise proceeds depend on Nasdaq-required stockholder approval; cashless exercise would generate no cash. Registration costs are borne by the issuer.
The August 2026 exercise of existing warrants generated ~$2.5 million gross before fees and expenses; net proceeds were intended for working capital and general corporate purposes.
Risk factors and disclosures
Resale registration covers shares equal to ~38% of post-exercise outstanding common stock; substantial sales or future issuances could pressure the share price, dilute holders and constrain future equity fundraising.
Warrants cannot be exercised before stockholder approval; the proposal failed at the September 2026 meeting and was adjourned to October 30, 2026. Repeated approval meetings add costs; approval is not assured.
Warrants carry a $4.06 exercise price; if market price does not exceed it, cash exercise may not occur. Cashless exercise could issue fewer shares but still materially dilute existing holders.
Disclosed risks include a history of losses and limited revenue, ability to raise capital and continue as a going concern, competition, security breaches, foreign-market expansion and Nasdaq reporting or listing compliance.
The auditor's report on FY2025 and FY2024 financial statements includes an explanatory paragraph citing substantial doubt about ability to continue as a going concern; M & K CPAS was engaged in July 2026 after Bush & Associates was dismissed.
Latest events from BIO-key International
- Proposal 4 voting remains open ahead of the October 30, 2026 meeting.BKYI
Proxy filing - Biometric IAM platform accelerates growth amid regulatory demand and global deployments.BKYI
Investor presentation - Annual meeting adjourned to October 2, 2026; voting remains open for eligible stockholders.BKYI
Proxy filing - Shareholders will vote on director elections, auditor, compensation, and a major warrant-related share issuance.BKYI
Proxy filing - Shareholders are asked to approve warrant-related share issuance that could dilute ownership by 53.2%.BKYI
Proxy filing - Q2 2026 revenue up 13%, net loss down 51%, with record margin and EMEA-driven growth.BKYI
Q2 2026 - Biometric IAM solutions see rapid growth, regulatory tailwinds, and a path to profitability in 2026.BKYI
Investor presentation - Proxy covers director elections, auditor change, executive pay, and governance practices.BKYI
Proxy filing - Q1 2025 saw sequential revenue growth, margin strength, and improved cash, but liquidity risks remain.BKYI
Q1 2025